WallStSmart

CapsoVision, Inc. Common Stock (CV)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 483903% more annual revenue ($67.38B vs $13.92M). MRK leads profitability with a 3.6% profit margin vs -210.1%. MRK earns a higher WallStSmart Score of 42/100 (D).

CV

Avoid

14

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -13.46

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CV.

MRKSignificantly Overvalued (-74.0%)

Margin of Safety

-74.0%

Fair Value

$84.93

Current Price

$144.52

$59.59 premium

UndervaluedFair: $84.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CV1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

Areas to Watch

CV4 concerns · Avg: 3.8/10
Price/BookValuation
12.3x4/10

Trading at 12.3x book value

Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$323.27M3/10

Smaller company, higher risk/reward

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CV

The strongest argument for CV centers on Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : CV

The primary concerns for CV are Price/Book, Revenue Growth, EPS Growth.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

CV profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

MRK is growing revenue faster at 4.7% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (42/100 vs 14/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CapsoVision, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company is headquartered in Saratoga, California.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?